Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Primärliteratur
Cabriales S, Bresnahan J, Testa D, et al: Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi’s sarcoma: a report of four cases. Oncol Nurs Forum 25: 67–70, 1998.
Guaglianone P, Chan K, Hanisch R, et al: Phase I clinical trial of liposomal daunorubicin (Daunoxome) in advanced malignancies. Proc ASCO 11: 35, 1992.
Sharma D, Muggia F, Lucci L, et al: Liposomal daunorubicin (VS103): tolerance and clinical effects in AIDS-related Kaposi’s sarcoma (KS) during a phase I study. Proc ASCO 9: 4, 1990.
Sekundärliteratur
Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
van Gemmern R: Gewebstoxizität und Paravasatbehandlung neuer Zytostatika. Krankenhauspharmazie 17: 471–473, 1996.
Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.
Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6. Auflage: 1–17, 1999.
Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2002). Daunorubicin liposomal. In: Paravasation von Zytostatika. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3799-4_20
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3799-4_20
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-3800-7
Online ISBN: 978-3-7091-3799-4
eBook Packages: Springer Book Archive